The EGFr-targeted drug cetuximab demonstrates clinical efficacy in first- [7,8], second- [9], and third-line [10] treatment alone or in combination with chemotherapy in patients with RAS wild-type metastatic colorectal cancer. Here, EGFR is linked to metastatic colorectal cancer.